![]() |
市場調查報告書
商品編碼
1827703
2025年血液培養檢測全球市場報告Blood Culture Tests Global Market Report 2025 |
近年來,血液培養檢測市場規模迅速擴張,從2024年的67.9億美元成長到2025年的75.1億美元,複合年成長率為10.5%。預測期內的成長歸因於感染疾病率的上升、人口老化、醫療基礎設施的進步、研發的不斷加強。
預計未來幾年血液培養檢測市場將快速成長,到2029年將達到129億美元,複合年成長率為14.5%。預測期內的成長主要源自於醫院內感染的增加、照護現場(POC) 需求的不斷成長、醫療保健支出的不斷成長以及監管部門的核准。預測期內的主要趨勢包括遠端醫療和遠端檢測、自動化和人工智慧、多重檢測、敗血症管理以及感染疾病監測。
血液培養是用於識別血液中致病微生物的診斷程序。這些檢測在檢測血液樣本中由各種微生物(包括細菌、酵母菌和其他外來生物)引起的感染疾病方面發揮著重要作用。
血液培養檢測主要採用傳統/手動和自動化方法。傳統或手動方法用於檢測血液檢體中的細菌、酵母菌和其他微生物等入侵者。手動檢測需要熟練的人員進行實際檢測並解釋結果。血液培養產品包括利用基於培養的技術、分子技術、微陣列、PCR(聚合酵素鏈鎖反應)、PNA-FISH(肽核酸螢光原位雜合反應)和蛋白質組學技術的耗材、設備、軟體和服務。這些技術用於檢測菌血症、真菌血症和分枝桿菌感染疾病。血液培養檢測通常用於醫院實驗室、參考實驗室、學術實驗室和其他檢測機構。
2025年春季美國關稅突然上調及其引發的貿易摩擦,對醫療設備領域產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰進一步加劇了形勢,因為由於關稅而更換供應商通常需要醫療設備重新認證,導致市場准入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分,該系列提供血液培養檢測市場統計數據,例如全球市場規模、區域佔有率、血液培養檢測市場佔有率的競爭對手、詳細的血液培養檢測細分市場、市場趨勢和機遇,以及您在血液培養檢測行業取得成功所需的數據。本血液培養檢測市場研究報告對該行業的現狀和未來趨勢進行了詳細分析,為您提供所需的一切觀點。
未來五年的預測成長率為14.5%,較我們先前對該市場的預測略有下降0.2%。下降的主要原因是美國與其他國家之間的關稅影響。這項影響將透過對來自比利時和瑞典等主要地區的富集培養基和自動檢測感測器徵收關稅直接影響美國,這可能導致敗血症診斷試劑供應減少,檢測成本上升。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響,這項影響也將更加廣泛。
感染疾病率的上升預計將推動血液培養檢測市場的成長。感染疾病是由病毒、細菌、真菌和寄生蟲等病原體引起的。這些有害微生物從外部或透過與受感染者接觸進入人體。 COVID-19、結核病、流感、麻疹、愛滋病毒和鏈球菌性感染疾病等疾病會導致暫時不適、嚴重組織損傷甚至死亡。世界衛生組織 (WHO) 已將感染疾病確定為全球第二大死因。感染疾病的增加推動了對血液培養檢測的需求,以確定患者是否患有可能危及生命的菌血症或敗血症。例如,根據英國衛生安全局 2024 年 8 月的報告,截至 2022 年 12 月 31 日,英國。截至 2023 年 5 月 31 日,已通報新增 21 例病例,主要在英格蘭,蘇格蘭通報 1 例。因此,感染疾病的盛行率不斷上升,推動了對血液培養測試的需求。
抗生素抗藥性細菌的增加預計將推動未來血液培養檢測市場的成長。抗生素抗藥性是指細菌、病毒和其他微生物抵抗以前可有效治療其引起的感染疾病的抗生素和抗菌藥物的作用的能力。抗生素抗藥性感染疾病的增加需要更全面的診斷測試,包括血液培養測試,以確定最有效的治療方法。例如,根據美國政府間組織世界衛生組織 (WHO) 2023 年 11 月的報告,抗生素抗藥性感染疾病預計將從 2030 年的 1 兆美元增加到 2050 年的 1 兆至 3.4 兆美元之間。因此,抗生素抗藥性增加導致的需求不斷成長,促進了血液培養檢測市場的成長。
技術創新已成為影響血液培養檢測市場的突出趨勢。在製藥、生技藥品、營養保健品和醫療設備等充滿活力的產業格局中,技術創新是滿足不斷變化的產業需求的關鍵。高效且經濟地將新產品推向市場的迫切需求促使製造商開發尖端的血液培養檢測技術。值得注意的是,Labcorp 於 2022 年 5 月推出了 Labcorp OnDemand™ 家用採集試劑套件。這款創新試劑套件利用乾血技術從少量血液樣本中測量糖化血紅蛋白 (HbA1c),為使用者提供隨時間推移的平均血糖值洞察。這些技術進步不僅提高了準確性和安全性,還使人們能夠舒適地在家中方便地監測自己的健康狀況,進一步推動了血液培養檢測市場的成長。
有機血液培養檢測市場的主要企業正致力於開發先進技術,例如臨床化學技術,旨在透過提供綜合檢測解決方案來提高診斷準確性、縮短週轉時間並加強患者管理,從而全面洞察感染疾病及相關健康問題。臨床化學技術是指主要用於分析體液(例如血液)以測量化學成分和評估健康狀況的診斷方法和設備。例如,2024年4月,總部位於中國的醫療醫療設備公司邁瑞醫療國際有限公司推出了一個中型實驗室。這些創新體現了邁瑞致力於支持中型實驗室的決心,透過提供簡單有效的解決方案來增強診斷能力,同時滿足醫療專業人員日益成長的需求。
2022年4月,總部位於印度的體外診斷解決方案提供商BioMerieux India Pvt Ltd收購了Specific Diagnostics,收購金額未揭露。此次收購旨在透過提供創新的體外診斷解決方案來改善公眾健康。 Specific Diagnostics是一家總部位於印度的公司,生產SPECIFIC REVEAL Rapid AST系統。
血液培養檢測市場的主要企業包括 Becton、Dickinson and Company、BioMerieux SA、Thermo Fisher Scientific Inc.、Luminex Corporation、Danaher Corporation、Terumo Corporation、Bruker Corporation、F. Hoffmann-La Roche AG、Biobase Biotech Co. Ltd.、Scenker Biological Technology Co. Ltd.、Bull AG、Ahx、as Ltd.、Ahators、Hiator Technology Co. Ltd.、Autobio Diagnostics Co. Ltd.、Axiom Laboratories、Biosystems Inc.、BINDER GmBH、Roche Diagnostics、Mikroscan Technologies Inc.、Labotronics Ltd.、Hardy Diagnostics、OpGen Inc.、Meditech Technologies India Private Limited、西門子、雅培科、醫學. Diagnostics、Bio-Rad Laboratories Inc.、Hologic Inc.、Quidel Corporation、Cop行業 Diagnostics Inc.、Greiner Bio-One International GmbH、Carl Zeiss AG、Nanosphere Health Sciences、GenMark Diagnostics、Meridian Bioscience Inc. 和尼康公司。
2024年血液培養檢測市場最大的地區是北美。血液培養檢測市場報告涵蓋以下地區:亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
血液培養檢測市場報告涵蓋的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。
血液培養檢測包括營業單位從微量採樣技術和血液化學分析儀中獲得的收益。市場規模包括服務提供者銷售或包含在服務產品中的相關商品的價值。僅包括營業單位之間交易或銷售給最終消費者的商品和服務。
Blood culture tests are diagnostic procedures designed to identify disease-causing microorganisms present in the bloodstream. These tests play a crucial role in detecting infections caused by various microorganisms such as bacteria, yeast, and other foreign invaders in a blood sample.
The primary methods employed in blood culture tests include conventional/manual methods and automated methods. The conventional or manual method is utilized to detect invaders like bacteria, yeast, and other microorganisms in a blood specimen. Manual testing involves the hands-on examination and interpretation of results by skilled testers. Blood culture products encompass consumables, instruments, and software and services that leverage technologies such as culture-based technology, molecular technologies, microarrays, PCR (polymerase chain reaction), PNA-FISH (peptide nucleic acid - fluorescent in situ hybridization), and proteomics technology. These technologies are applied in the detection of bacteremia, fungemia, and mycobacterial infections. Blood culture tests are commonly utilized by hospital laboratories, reference laboratories, academic research laboratories, and other testing facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The blood culture tests market research report is one of a series of new reports from The Business Research Company that provides blood culture tests market statistics, including blood culture tests industry global market size, regional shares, competitors with a blood culture tests market share, detailed blood culture tests market segments, market trends and opportunities, and any further data you may need to thrive in the blood culture tests industry. This blood culture tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The blood culture tests market size has grown rapidly in recent years. It will grow from $6.79 billion in 2024 to $7.51 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increase in prevalence of infectious diseases, aging population, advances in healthcare infrastructure, rise in research and development.
The blood culture tests market size is expected to see rapid growth in the next few years. It will grow to $12.9 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to rising hospital-acquired infections, growing demand for point-of-care (poc) testing, increased healthcare spending, regulatory approvals. Major trends in the forecast period include telemedicine and remote testing, automation and ai, multiplex testing, sepsis management, infectious disease surveillance.
The forecast of 14.5% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on enriched culture media and automated detection sensors, sourced from key regions such as Belgium and Sweden, which could lead to reduced availability of sepsis diagnostics and higher testing costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of infectious diseases is expected to drive the growth of the blood culture test market. Infectious diseases are caused by pathogens such as viruses, bacteria, fungi, and parasites. These harmful microorganisms can enter the body from external sources or through contact with an infected individual. Diseases like COVID-19, tuberculosis, the flu, measles, HIV, and strep throat can cause temporary discomfort, severe tissue damage, or even death. The World Health Organization identifies infectious diseases as the second leading cause of death globally. This increase in infectious disease cases has fueled the demand for blood culture tests, which help determine whether a patient has bacteremia or septicemia, potentially life-threatening conditions. For example, in August 2024, according to a report by the UK Health Security Agency, as of December 31, 2022, there were 3,732 confirmed mpox cases in the UK, primarily in England. By May 31, 2023, 21 additional cases were reported, mainly in England, with one in Scotland. As a result, the growing incidence of infectious diseases is driving demand for blood culture tests.
The rise in antibiotic resistance is expected to drive the growth of the blood culture test market in the future. Antibiotic resistance refers to the ability of bacteria, viruses, or other microorganisms to resist the effects of antibiotics or antimicrobial drugs that were previously effective in treating infections caused by these organisms. The increase in antibiotic-resistant infections requires more comprehensive diagnostic testing, including blood culture tests, to identify the most effective treatment options. For example, in November 2023, according to a report from the World Health Organization, a US-based intergovernmental organization, antibiotic-resistant infections are projected to increase from $1 trillion in 2030 to between $1 trillion and $3.4 trillion by 2050. Thus, the rising demand due to increasing antibiotic resistance is contributing to the growth of the blood culture test market.
Technological innovation emerges as a prominent trend influencing the blood culture test market. In the dynamic landscape of pharmaceuticals, biologics, nutraceuticals, and medical devices, innovation is key to meeting evolving industry requirements. The imperative to bring new products to market efficiently and cost-effectively has led manufacturers to develop cutting-edge blood culture testing technologies. Notably, Labcorp introduced the Labcorp OnDemandTM at-home collection kit in May 2022. This innovative kit utilizes dried blood technology to measure hemoglobin A1c from a small blood sample, providing users with insights into their average blood sugar levels over time. Technological advancements like this not only enhance accuracy and safety but also enable individuals to monitor their health conveniently from the comfort of their homes, fostering the growth of the blood culture test market.
Major companies in the organic blood culture tests market are focusing on developing advanced technologies, such as clinical chemistry technologies, to improve diagnostic accuracy, decrease turnaround times, and enhance patient management through integrated testing solutions that deliver comprehensive insights into infections and related health issues. Clinical chemistry technologies refer to diagnostic methods and instruments utilized to analyze bodily fluids, primarily blood, to measure chemical components and evaluate health conditions. For example, in April 2024, Mindray Medical International Limited, a medical device company based in China, launched mid-volume laboratories. These innovations demonstrate Mindray's dedication to supporting mid-volume laboratories by offering simple yet effective solutions that boost diagnostic capabilities while meeting the growing demands of healthcare providers.
In April 2022, BioMerieux India Pvt Ltd, a provider of in vitro diagnostic solutions based in India, acquired Specific Diagnostics for an undisclosed amount. This acquisition aims to improve public health by delivering innovative in vitro diagnostic solutions. Specific Diagnostics is an India-based company that produces the SPECIFIC REVEAL Rapid AST system for testing.
Major companies operating in the blood culture tests market include Becton, Dickinson and Company, BioMerieux SA, Thermo Fisher Scientific Inc., Luminex Corporation, Danaher Corporation, Terumo Corporation, Bruker Corporation, F. Hoffmann-La Roche AG, Biobase Biotech Co. Ltd., Scenker Biological Technology Co. Ltd., Bulldog Bio, Anaerobe Systems Inc., Himedia Laboratories Pvt. Ltd., Autobio Diagnostics Co. Ltd., Axiom Laboratories, Biosystems Inc., BINDER GmBH, Roche Diagnostics, Mikroscan Technologies Inc., Labotronics Ltd., Hardy Diagnostics, OpGen Inc., Meditech Technologies India Private Limited, Siemens Healthineers, Abbott Laboratories, Cepheid, T2 Biosystems Inc., Beckman Coulter Inc., Accelerate Diagnostics, Bio-Rad Laboratories Inc., Hologic Inc., Quidel Corporation, Copan Diagnostics Inc., Greiner Bio-One International GmbH, Carl Zeiss AG, Nanosphere Health Sciences, GenMark Diagnostics, Meridian Bioscience Inc., Nikon Corporation
North America was the largest region in the blood culture tests market in 2024. The regions covered in the blood culture tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the blood culture tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The blood culture tests include revenues earned by entities by micro sampling technology and blood chemistry analyzer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Blood Culture Tests Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on blood culture tests market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for blood culture tests ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The blood culture tests market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.